TSTakiyah D. Starks

Takiyah D. Starks

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takiyah D. Starks has a total of 124 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Empowering a Clinical Research Team to Recruit and Retain Hispanic and African American Participants for the DAWN Alzheimer's Research Study

    by Takiyah D. Starks, Shawnta Lloyd, Kristy A. Terrell, Charles T Fennell, Lakisha D Hinnant, Ke'YOna Barton, Rodney Witherspoon, Brianna Eley, Larry D Adams, Mary E Douglas, et al.

    Background: The DAWN study will build a large genomics resource for AD research in individuals with African (Af) and Hispanic/Latino (H/L) ancestry. Clinical Research Coordinators (CRCs) are recruiting 5,000 Af, 4,000 African Americans (AA) and 4,000 H/L participants from the US and ten African sites. Study recruitment is done through community engagement in rural and urban settings. Coordinators on the front lines play an invaluable role in the success of reaching DAWN goals and assuring participant satisfaction as well as study trustworthiness. Often too little investment is made in this indispensable group. Method: DAWN utilizes a team science approach for recruiting AA and HI participants across four U.S. sites. Outreach and Recruitment (OR) efforts are led by an OR core team. Clinical trainings are led by a Coordinating Site team and by managers at each site. Weekly virtual meetings hosted by the Coordinating Site, and monthly collaborators meetings offer bi‐directional learning between CRCs and trainers. An annual CRC meeting creates platforms for advancing professional development, clinical skills, culturally relevant and patient‐centered recruitment strategies, and camaraderie among cross‐site peers. At face‐to‐face convenings teams review study goals and expectations, celebrate milestones, and empower CRCs to identify organizational, administrative and personal challenges and successes across sites, including collaborating across‐sites to achieve enrollment goals. Result: Nineteen DAWN CRCs are of AA and HI descent, representative of the recruitment populations. Approximately, 85% are female and all have at least a bachelor's degree. In the first two years, DAWN CRCs met enrollment goals with (1,616 AAs and 1,599 HIs). They identified 26 impediments and 14 retention strategies to improve recruitment efficiencies. Top strategies involved building community trust, CRC safety, providing additional in‐person trainings and providing resources for community. CRCs at all DAWN sites have assisted at least one other site in their recruitment. Conclusion: Multi‐site efforts to provide important ancestral diversity to the global Alzheimer's genomics research effort will continue needing to identify roles, impediments and strategies for successful recruitment and retention of participants. Listening to the voices of CRCs and investing in their development are important strategies for recruitment success and employee retention.

  • Open Access

    Comparing Alzheimer's genes in African, European, and Amerindian induced pluripotent stem cell–derived microglia

    by Sofia Moura, Luciana Bertholim Nasciben, Aura M. Ramirez, Lauren Coombs, Joe Rivero, Derek J. Van Booven, Brooke A. DeRosa, Kara L. Hamilton‐Nelson, Patrice L. Whitehead, Larry D. Adams, et al.

    INTRODUCTION: Genome‐wide association studies (GWAS) studies in Alzheimer's disease (AD) demonstrate ancestry‐specific loci. Previous studies in the regulatory architecture have only been conducted in Europeans (EUs), thus studies in additional ancestries are needed. Given the prevalence of AD genes expressed in microglia, we initiated our studies in induced pluripotent stem cell (iPSC) ‐derived microglia. METHODS: We created iPSC‐derived microglia from 13 individuals of either high Amerindian (AI), African (AF), or EU global ancestry, including both AD and controls. RNA‐seq, ATAC‐seq, and pathway analyses were compared between ancestries in both AD and non‐AD genes. RESULTS: Twelve AD genes were differentially expressed genes (DEGs) and/or accessible between ancestries, including ABI3 , CTSB , and MS4A6A . A total of 5% of all genes had differential ancestral expression, but differences in accessibility were less than 1%. The DEGs were enriched in known AD pathways. DISCUSSION: This resource will be valuable in evaluating AD in admixed populations and other neurological disorders and understanding the AD risk differences between populations. Highlights: First comparison of the genomics of AI, AF, and EU microglia. Report differences in expression and accessibility of AD genes between ancestries. Ancestral expression differences are greater than differences in accessibility. Good transcriptome correlation was seen between brain and iPSC‐derived microglia. Differentially expressed AD genes were in known AD pathways.


  • Open Access

    Understanding Challenges of Recruiting African Americans for Genomic Studies in Alzheimer’s Disease Beyond Trust

    by Takiyah D. Starks, Allison M Caban‐Holt, Kristy A. Terrell, Jesseca Crawford, Ashley Gregory, Larry D. Adams, Michael L. Cuccaro, Jonathan L. Haines, Christiane Reitz, Jeffery M. Vance, et al.

    Background: Black/African Americans (B/AAs) remain underrepresented in Alzheimer’s disease (AD) research and clinical trials. As a part of understanding genetics and genomics of AD, four U.S sites are recruiting 4,000 African Americans over age 60 for research participation. We identify challenges and propose solutions for recruiting AA’s using community based and grass roots efforts.Method: An important strategy for recruiting B/AAs for research is to engage researchers and staff in face‐to‐face interactions outside of the medical/academic campus. We analyzed steps required to move individuals from initial research interest to their enrolling in the study, over a 6‐month period. During community outreach activities, interested individuals provided basic demographic data, and level of interest in AD research. Research staff followed‐up by telephone up to three times, within 48 ‐72 hours, to answer questions and schedule a home visit. Scheduled participants were also contacted one week before the study appointment, and a confirmation letter was sent. Participants were called the day before and the day of the home visit to assure participant availability, creating up to eight touch points prior to enrollment.Result: We enrolled 67 of the 129 B/AAs scheduled over a 6‐month period. Thirty three of the 67 interested participants (49%) were scheduled on the first attempt, n = 26 (39%) on the second attempt and n = 8 (12%) on the third attempt. All enrollees (100%) were called a week before the appointment and a confirmation email was sent. Thirteen (10%) of scheduled appointments were cancelled due to: 1) inability to reach them (62%), 2) no longer interested (15%), 3) feared the blood draw (15%) and 4) time constraints (8%).Conclusion: Despite using culturally sensitive research teams, materials and advertisements, reliability of recruiting B/AAs for genetic research studies using grass roots methods remains elusive. Appointment cancellations due to fear of blood draws, family issues and time limitations are key factors, but understanding reasons for loss of contact and interest should be further investigated. Closing gaps between B/AAs’ research interest and their actual enrollment will require multiple and simultaneous recruitment strategies that might require more than trust.

  • Open Access

    Gene expression and chromatin accessibility comparison in iPSC-derived microglia in African, European, and Amerindian genomes in Alzheimer’s patients and controls

    by Sofia Moura, Luciana Bertholim Nasciben, Aura M. Ramirez, Lauren Coombs, Joe Rivero, Derek J. Van Booven, Brooke A. DeRosa, Kara L. Hamilton-Nelson, Patrice L. Whitehead, Larry D. Adams, et al.

    Alzheimer’s disease (AD) risk differs between population groups, with African Americans and Hispanics being the most affected groups compared to non-Hispanic Whites. Genetic factors contribute significant risk to AD, but the genetic regulatory architectures (GRA) have primarily been studied in Europeans. Many AD genes are expressed in microglia; thus, we explored the impact of genetic ancestry (Amerindian (AI), African (AF), and European (EU)) on the GRA in iPSC-derived microglia from 13 individuals (∼4 each with high global ancestry, AD and controls) through ATAC-seq and RNA-seq analyses. We identified several differentially accessible and expressed genes (2 and 10 AD-related, respectively) between ancestry groups. We also found a high correlation between the transcriptomes of iPSC-derived and brain microglia, supporting their use in human studies. This study provides valuable insights into genetically diverse microglia beyond the analysis of AD.

  • Open Access

    Maya Angelou Center for Health Equity Caregiver College: a culturally‐relevant training for African American Alzheimer’s disease caregivers

    by Allison M Caban‐Holt, Takiyah D. Starks, Shawnta' Lloyd, Anita Ford, Sole' McCall, Samuela B. Eale, Lori Fuller, Goldie S. Byrd

    Background: African American (AA) caregivers of patients with Alzheimer’s disease (AD) and related disorders can play a critical role in maintaining patient health. The Maya Angelou Center for Health Equity at Wake Forest University School of Medicine Caregiver College (MC2) aims to (1) improve informal caregivers’ knowledge of AD and related disorders, (2) enhance the quality of life for AD patients and caregiver’s by providing awareness of and access to resources that can help reduce caregiver burden, (3) provide strategies to effectively manage patient symptoms associated with AD, and (4) fill gaps in culturally relevant health education and awareness on AD, brain health, and dementia caregiving skills for AAs.Method: The 40‐hour inaugural session of MC2 was conducted in‐person in October 2022. Educational sessions were facilitated by experts in various fields including AD, social work, nursing, aging, nutrition, and pharmacy. Topics covered over the course of the educational week included: Alzheimer’s Disease Overview, Health Disparities in AAs, Risk Factors for AD, End of Life Planning, and Caregiver Health. The 21‐item Dementia Knowledge Assessment Tool (DKAT), version 2 (Toye, et al. 2013) was used to track changes in AD knowledge and awareness. A DKAT pre‐test was administered before the educational sessions began on Day 1, and a post‐test assessment was administered at the end of the last educational session on Day 5.Result: Attendees (N = 21) are African American (100%), primarily female (90.48%), with an average age of 66.8 years (range 42‐82 years, 1 missing value). DKAT assessments from the week‐long educational training, showed an 8% increase in knowledge about AD in this sample of dementia caregivers based on a 5.7 percentage point increase on the DKAT from an average of 71.4% correct pre‐training to an average of 77.1% correct post‐training.Conclusion: Findings suggest that community‐based educational training is a useful strategy for improving AD knowledge and resource awareness for AA informal caregivers. Results will be used to expand this training to include community members who will be engaged through presentations by attendees of the MC2.

  • Open Access

    Perceptions of Brain donation and Medical Research Among African American Individuals: Implications for Recruitment and Retention into Alzheimer’s Research

    by Takiyah D. Starks, Allison M Caban‐Holt, Michael L. Cuccaro, Tayla Ford, Shawnta' Lloyd, Larry D. Adams, Johnathan L Haines, Christiane Reitz, Jeffery M. Vance, Margaret A. Pericak‐Vance, et al.

    Background: African Americans (AAs) are twice as likely to have Alzheimer’s disease (AD) as their White counterparts; yet, this population is largely missing from brain donation research. According to the National Alzheimer’s Coordinating Center, merely 2% of brain donations are obtained from AAs. Medical mistrust among AAs has been well‐documented as a barrier to medical research participation. The purpose of this study was to expand our understanding of AA perceptions of medical research and brain donation.Method: Using validated survey items, a 35‐item cross‐sectional survey was developed to understand attitudes and beliefs about medical research and brain donation among AAs. Surveys were administered via REDCap (Research Electronic Data Capture) and paper in Florida, New York, North Carolina and Ohio, United States from November 2021 to September 2022. Descriptive analysis of data on research participation and trust in medical research was conducted using SAS® software version 9.4.Result: A total of 227 AAs participated in this study with about three‐quarters of participants being female. Approximately 90% of AAs reported being born in the US, and nearly half of the sample reported receiving some college education or higher. Only 10.6% of participants reported being very likely to donate their brain to research after death. Despite the low percentage of AAs willing to donate their brain to research, 77.1% had a positive view of medical research and 72.7% trusted researchers in general. In fact, participants perceived that it is “very important” to participate in medical research to help future generations (78.4%), to learn more about AD (66.5%), and receive medical information (56.8%).Conclusion: Most AAs in this study reported strong trust in medical research and researchers. Medical mistrust may not be a significant barrier to participation in brain donation or AD research for AAs in this sample. Improved health literacy in AD research and brain donation procedures may facilitate engagement of AAs to participate in such research. Findings from this study will be used to inform the development of a culturally relevant health literacy program, with a focus on brain donation and AD research, to enhance opportunities for recruitment and retention of AAs.


  • Open Access

    Uncovering the Role of an ABCA7 Frameshift Deletion in African American Alzheimer’s Disease Cellular Pathology

    by Brooke A. DeRosa, Younji Nam, Charles G. Golightly, Shaina A. Simon, Jamie Arvizu, Larry D. Adams, Takiyah D. Starks, Juliana Laverde‐Paz, Holly N. Cukier, Jeffery M. Vance, et al.

    Background: The ATP Binding Cassette Subfamily A Member 7 (ABCA7) gene is a risk factor for Alzheimer’s disease (AD). While ABCA7 has been implicated as a genetic determinant of AD across populations, the risk effect is the strongest in African Americans (AAs). We previously identified a common 44 base pair deletion in ABCA7 (p.Arg578Alafs) that is predicted to truncate the protein and is significantly associated with AD in AAs (frequency in cases = 15.2%, cognitively unimpaired (CU) = 9.74%, p = 1.41×10−5). Clinically, deletion homozygotes are similar to deletion heterozygotes, supporting dominant gain‐of‐function as a putative disease‐causing mechanism. We sought to determine if the deletion transcript is stable and if the truncated protein is expressed as steps to understanding the mechanism leading to AD risk.Method: RT‐PCR analysis of heterozygotes was conducted to assess the stability of the deletion transcript. FLAG‐tagged Arg578Alafs and wildtype ABCA7 vectors were constructed then overexpressed in HEK293APPsw cells. Western blot analysis of FLAG‐Arg578Alafs was performed to determine if the deletion produces a truncated protein. Induced pluripotent stem cell (iPSC) lines from six AA individuals with AD bearing the Arg578Alafs mutation (three heterozygous; three homozygous) were created in pair with isogenic CRISPR‐corrected control lines. These iPSC lines were validated for pluripotency, genomic stability, and lack of off‐target editing. The isogenic ABCA7 deletion and CRISPR‐corrected control iPSC lines will be differentiated into microglia and neurons and functionally assessed for cell type‐specific AD phenotypes.Result: Initial results comparing AD patients to CU individuals show that patient‐derived microglia have normal rates of phagocytosis but are impaired in the uptake and clearance of fibrillar Aβ. RT‐PCR analysis of the deletion in heterozygotes demonstrates that a stable RNA transcript is expressed from the ABCA7 deletion allele. Western blot analysis of overexpressed FLAG‐Arg578Alafs shows that the truncated protein is expressed, albeit at low levels compared to the wildtype protein.Conclusion: This ABCA7 deletion produces a stable transcript which appears to be translated into low levels of protein. This supports a potential gain of function as the disease risk mechanism. Studies in isogenic lines will further elucidate the functional effects of this ABCA7 deletion on AD pathology in AAs.

  • Impact of the COVID‐19 Pandemic on Dementia Caregivers in the South US

    by Takiyah D. Starks, Shawnta' Lloyd, Allison M Caban‐Holt, Jarrel Clark, Goldie S. Byrd

    Background: Compared to their non‐caregiving peers, caregivers of persons with dementia (PWD) endure higher psychological distress, social isolation and increased morbidity and disability. Stress and isolation experienced by caregivers during the COVID‐19 pandemic have added to caregiver burden and worsened health. The objective of this study was to obtain a greater understanding of the health and needs of informal caregivers of PWD during the COVID‐19 pandemic.Method: Using a cross‐sectional questionnaire, we attained demographic data, characteristics of caregiving during the COVID‐19 pandemic, mental health status, COVID‐19 testing and illness, and protective measures taken to prevent infection with COVID‐19 among caregivers of PWD. From March 2021 to August 2021, respondents were recruited through the Maya Angelou Center for Health Equity’s Alzheimer’s disease (AD) registry. Descriptive statistics (frequency and proportions) of demographic, caregiving, health, and COVID‐19 related data for caregivers of PWD was conducted using SAS® software version 9.4.Result: A total of 274 caregivers of PWD participated in the study. More than half of caregivers were women (56.57%), and approximately 73% of caregivers were married. The racial composition of the majority of caregivers included African American (44.16%), Non‐Hispanic White (26.64%), and Native American (20.44%). Most caregivers were providing care for parents (59.86%) or a partner (21.17%). Nearly 46% of caregivers reported experiencing stress, but not being burnt out. Almost 47% of caregivers reported high psychological distress during the COVID‐19 pandemic. In addition to caregiving stressors due to the COVID‐19 pandemic, caregivers also experienced behavioral changes in their household; more than half of caregivers experienced increased interpersonal conflict with loved ones, friends, or co‐workers. The top 3 needs reported during the COVID‐19 pandemic included support with caregiving, medical care, and food.Conclusion: Approximately half of caregivers of PWD experienced stress and psychological distress during the COVID‐19 pandemic. In addition to the stress of caregiving, caregivers lacked support for necessary medical services and social needs. The data collected from caregivers during the COVID‐19 pandemic will be used to develop recommendations to support informal caregivers during emergency situations.

  • Genetic architecture of RNA editing regulation in Alzheimer’s disease across diverse ancestral populations

    by Olivia K Gardner, Derek Van Booven, Lily Wang, Tianjie Gu, Natalia K Hofmann, Patrice L Whitehead, Karen Nuytemans, Kara L Hamilton-Nelson, Larry D Adams, Takiyah D Starks, et al.

    Most Alzheimer’s disease (AD)-associated genetic variants do not change protein coding sequence and thus likely exert their effects through regulatory mechanisms. RNA editing, the post-transcriptional modification of RNA bases, is a regulatory feature that is altered in AD patients that differs across ancestral backgrounds. Editing QTLs (edQTLs) are DNA variants that influence the level of RNA editing at a specific site. To study the relationship of DNA variants genome-wide, and particularly in AD-associated loci, with RNA editing, we performed edQTL analyses in self-reported individuals of African American (AF) or White (EU) race with corresponding global genetic ancestry averaging 82.2% African ancestry (AF) and 96.8% European global ancestry (EU) in the two groups, respectively. We used whole-genome genotyping array and RNA sequencing data from peripheral blood of 216 AD cases and 212 age-matched, cognitively intact controls. We identified 2144 edQTLs in AF and 3579 in EU, of which 1236 were found in both groups. Among these, edQTLs in linkage disequilibrium (r2 > 0.5) with AD-associated genetic variants in the SORL1, SPI1 and HLA-DRB1 loci were associated with sites that were differentially edited between AD cases and controls. While there is some shared RNA editing regulatory architecture, most edQTLs had distinct effects on the rate of RNA editing in different ancestral populations suggesting a complex architecture of RNA editing regulation. Altered RNA editing may be one possible mechanism for the functional effect of AD-associated variants and may contribute to observed differences in the genetic etiology of AD between ancestries.


  • Open Access

    Assessment of AD‐related plasma biomarkers in diverse ancestral populations

    by Anthony J. Griswold, Farid Rajabli, Catherine Garcia‐Serje, Kara L. Hamilton‐Nelson, Larry D. Adams, Sergio Tejada, Pedro Ramon Mena, Takiyah D. Starks, Patrice L. Whitehead, Concepcion Silva‐Vergara, et al.

    Background: Plasma proteins as biomarkers for the differential diagnosis of AD from other similar neurodegenerative disorders, as well as the identification of preclinical AD, has recently been well supported across several large AD cohorts. However, these are composed primarily of individuals of non‐Hispanic European ancestry. Few studies have been performed in African‐American or Hispanic/Latinx AD populations to determine if plasma biomarkers are also useful in these populations. Given the differences in AD risk loci found across ancestries, the application of these biomarkers in diverse populations is not assured. Therefore, the aim of this study is to explore the utility of plasma biomarkers in AD, MCI and at‐risk family members from diverse ancestral backgrounds.Method: As part of ongoing initiatives to understand AD in individuals of diverse ancestry, we are measuring the plasma level of biomarkers in a cohort of more than 3,000 individuals. This includes: 999 African Americans (248 AD cases, 591 controls, 160 MCI), 581 Puerto Ricans (223 AD cases, 208 controls, 150 MCI), 1052 Puerto Ricans in families (411 AD cases, 413 controls, 228 MCI), 98 Cubans (23 AD cases, 39 controls, 36 MCI), and 117 Peruvians (33 AD cases, 75 controls, 9 MCI). We will also have data on autopsy confirmed European AD cases (37) and a cohort of Amish individuals (∼400 AD cases, ∼200 MCI, and ∼500 controls). Plasma proteins tested are Aβ42, Aβ40, total Tau, and p‐Tau181 using Simoa chemistry assays (Quanterix HD‐X). All measurements are performed in duplicate and data analysis performed using HD‐X Analyzer Software v1.6.Result: Measurement and analysis of biomarkers in this diverse dataset is currently underway and will be completed in a few months. These results will allow a direct comparison of biomarker analysis related to AD diagnosis between European, African, and Amerindian ancestries. Moreover, a family‐based design for over 1000 Puerto Rican individuals will be the first to identify potential heritable trends in biomarker levels.Conclusion: This study is critical to being to understand how plasma biomarkers for AD may vary across diverse ancestries and whether previous findings will be generalizable and useful for all individuals, regardless of ancestry.